Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | MAX | P61244 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593456 | 0.89 | HCAR3 (0.50) | HCAR3KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7916870 | 0.85 | HCAR3 (0.59) | HCAR3KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL7596213 | 0.83 | ALDH1A1 (0.51) | HCAR3KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7596953 | 0.83 | HCAR3 (0.48) | HCAR3KMT2AALDH1A1KDM4E | |
| SCHEMBL7593563 | 0.82 | HCAR3 (0.46) | HCAR3KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL7593606 | 0.81 | HCAR3 (0.46) | HCAR3KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7598800 | 0.80 | LTB4R (0.54) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7592996 | 0.78 | POLB (0.53) | HCAR3KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7593562 | 0.77 | KMT2A (0.43) | HCAR3KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL7594892 | 0.77 | LTB4R (0.62) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6369092-B1 | Method for treating neoplasia by exposure to substituted benzimidazole derivatives | CELL PATHWAYS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | HCAR3 3869/4885KMT2A 1590/4885MEN1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.